Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Psychologist
|
| gptkbp:advocacy |
gptkb:ALS_Therapy_Development_Institute
gptkb:ALS_Association MDA |
| gptkbp:associatedWith |
inflammation
oxidative stress neurodegeneration glutamate toxicity |
| gptkbp:characterizedBy |
progressive muscle weakness
|
| gptkbp:clinicalTrials |
ongoing research
gene therapy studies drug efficacy studies stem cell therapy studies biomarker_studies |
| gptkbp:diseaseResistance |
clinical examination
varies by individual more common in men electromyography incidence increases with age prevalence varies by region |
| gptkbp:firstDescribedBy |
in the 19th century
|
| gptkbp:geneticDiversity |
SOD1 mutations
C9orf72 expansions FUS_mutations TARDBP_mutations |
| https://www.w3.org/2000/01/rdf-schema#label |
sporadic ALS
|
| gptkbp:impact |
gptkb:edaravone
social isolation motor neurons financial burden emotional stress riluzole caregiver responsibilities need for long-term care |
| gptkbp:inheritsFrom |
typically in adulthood
|
| gptkbp:legalEvent |
3 to 5 years after diagnosis
|
| gptkbp:notableFeature |
gptkb:Jason_Becker
gptkb:Stephen_Hawking gptkb:Morrissey gptkb:Lou_Gehrig gptkb:David_Niven |
| gptkbp:publicAccess |
gptkb:ALS_Ice_Bucket_Challenge
|
| gptkbp:researchFocus |
developing treatments
understanding causes |
| gptkbp:riskManagement |
environmental factors
age genetic factors |
| gptkbp:supports |
online forums
patient advocacy groups local_ALS_chapters |
| gptkbp:symptoms |
fatigue
difficulty speaking difficulty swallowing muscle cramps |
| gptkbp:type |
Motor Neuron Disease
|